OR WAIT null SECS
Will feature additional cell and gene therapy capacity
Applied StemCell, Inc. (ASC), a cell and gene therapy contract research organization/contract development and manufacturing organization (CRO/CDMO), is growing its current good manufacturing product (cGMP) facility. ASC has been completing cell banking and product manufacturing projects in its current cGMP suite and is now set on building four additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space.
The project, the company says, will increase its cell banking and cell product manufacturing capacity and allow ASC’s team to work on multiple manufacturing projects at the same time, including iPSC generation, gene editing, differentiation, and cell bank manufacturing for safe and efficacious therapeutic products. Construction is expected to commence within the next month.
“We are very excited to move forward with the expansion of our cGMP facility,” notes David Lee, PhD, head of GMP and quality. “Our team has been working closely with our clients to ensure delivery of high-quality clinical grade products. We thank our customers for their support and trust. With the addition of four cGMP cleanrooms, we will be able to assist a greater number of researchers focused on cell and gene therapy.”